Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

849 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.
Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Lau G, et al. Among authors: cheng al. Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385. Online ahead of print. Hepatology. 2025. PMID: 40384092
Corrigendum to "Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study".
Jain SS, Anderson SA, Steele JM, Wilson HC, Muniz JC, Soslow JH, Beroukhim RS, Maksymiuk V, Jacquemyn X, Frosch OH, Fonseca B, Harahsheh AS, Buddhe S, Ashwath RC, Thacker D, Maskatia SA, Misra N, Su JA, Siddiqui S, Vaiyani D, Vaikom-House AK, Campbell MJ, Klein J, Huang S, Mathis C, Cornicelli MD, Sharma M, Nagaraju L, Ang JY, Uppu SC, Ramachandran P, Patel JK, Han F, Mandell JG, Akam-Venkata J, DiLorenzo MP, Brumund M, Bhatla P, Eshtehardi P, Mehta K, Glover K, Dove ML, Aldawsari KA, Kumar A, Barfuss SB, Dorfman AL, Minocha PK, Yonts AB, Schauer J, Cheng AL, Robinson JD, Powell Z, Srivastava S, Chelliah A, Sanil Y, Hernandez LE, Gaur L, Antonchak M, Johnston M, Reich JD, Nair N, Drugge ED, Grosse-Wortmann L. Jain SS, et al. Among authors: cheng al. EClinicalMedicine. 2025 May 21;84:103268. doi: 10.1016/j.eclinm.2025.103268. eCollection 2025 Jun. EClinicalMedicine. 2025. PMID: 40496878 Free PMC article.
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma.
Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Cheng AL, Galle PR, Kaneko S, Kumada H, Kamble S, Norquist JM, Mody K, Wang A, Dubrovsky L, Llovet JM. Finn RS, et al. Among authors: cheng al. ESMO Open. 2025 Jun;10(6):105065. doi: 10.1016/j.esmoop.2025.105065. Epub 2025 May 27. ESMO Open. 2025. PMID: 40435872 Free PMC article. Clinical Trial.
849 results